{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T04:11:20Z","timestamp":1744431080907,"version":"3.40.4"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-00923-1","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T13:25:02Z","timestamp":1744377902000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Commentary on \u201creal world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: a meta-analysis of clinical studies\u201d"],"prefix":"10.1186","volume":"26","author":[{"given":"Ali Beheshti","family":"Namdar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoud","family":"Keikha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"issue":"1","key":"923_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40360-024-00832-9","volume":"26","author":"MA Karimi","year":"2025","unstructured":"Karimi MA, Norooziseyedhosseini H, Khademi R, Ghajary A, Kargar H, Abdollahi SS, Belbasi M, Naziri M, Deravi N, Hajihosseini S, Mofidi S, et al. Real world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: a meta-analysis of clinical studies. BMC Pharmacol Toxicol. 2025;26(1):43.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"5","key":"923_CR2","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/pst.2161","volume":"20","author":"BM Nugent","year":"2021","unstructured":"Nugent BM, Madabushi R, Buch B, Peiris V, Crentsil V, Miller VM, Bull J, Jenkins R. Heterogeneity in treatment effects across diverse populations. Pharm Stat. 2021;20(5):929\u201338.","journal-title":"Pharm Stat"},{"issue":"2","key":"923_CR3","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3390\/medicina59020324","volume":"59","author":"AM Moldovianu","year":"2023","unstructured":"Moldovianu AM, Stoia R, Vasilica M, Ursuleac I, Badelita SN, Tomescu AA, Preda OD, Bardas A, Cirstea M, Coriu D, et al. Real-world clinical outcomes and adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib: a single-center retrospective study. Medicina. 2023;59(2):324.","journal-title":"Medicina"},{"issue":"12","key":"923_CR4","doi-asserted-by":"publisher","first-page":"10374","DOI":"10.3390\/ijms241210374","volume":"24","author":"N Maher","year":"2023","unstructured":"Maher N, Mouhssine S, Matti BF, Alwan AF, Gaidano G. Treatment refractoriness in chronic lymphocytic leukemia: old and new molecular biomarkers. Int J Mol Sci. 2023;24(12):10374.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"923_CR5","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1080\/10428194.2024.2310150","volume":"65","author":"JA Yared","year":"2024","unstructured":"Yared JA, Lee TY, Cooke CE, Johnson A, Summers A, Yang K, Liu S, Tang B, Onukwugha E, et al. Disparity in treatment patterns among medicare beneficiaries diagnosed with chronic lymphocytic leukemia: an analysis of patient and contextual factors. Leuk Lymphoma. 2024;65(5):598\u2013608.","journal-title":"Leuk Lymphoma"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00923-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-00923-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00923-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T13:25:02Z","timestamp":1744377902000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-00923-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":5,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["923"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-00923-1","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"23 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"80"}}